$Kodiak Sciences (KOD.US)$ announces one-year topline data f...
$Kodiak Sciences (KOD.US)$ announces one-year topline data for its ABC Platform based investigational therapy tarcocimab tedromer from the pivotal BEACON study in patients with macular edema due to retinal vein occlusion (RVO)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment